PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor (PD-1 Inhibitors and PD-L1 Inhibitors), By Application (Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-small Cell Lung Cancer, and Others), By End Users (Hospital Pharmacies, Retail Pharmacies, and Onl

PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor (PD-1 Inhibitors and PD-L1 Inhibitors), By Application (Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-small Cell Lung Cancer, and Others), By End Users (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

PD-1 and PD-L1 inhibitors are important immune checkpoint inhibitors (ICIs) used as a front-line treatment for several types of cancer. These inhibitors are often used to treat Hodgkin lymphoma, kidney cancer, melanoma, and non-small cell lung cancer, among others. PD-1/PD-L1 inhibitors are drugs that help the body recognize and attack cancer cells. Thus, there is an increase in demand for PD-1 and PD-L1 inhibitors across the globe.

Market Dynamics:

Increase in prevalence of cancer, growing geriatric population, rise in awareness about immune checkpoint inhibitors, increase in focus on the development of safe and effective cancer treatment, and favorable government initiatives are major factors expected to propel growth of the global PD-1 and PD-L1 inhibitor market over the forecast period.

For instance, in October 2021, Merck received the U.S. Food and Drug Administration (USFDA) approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, to treat patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1, as determined by an FDA-approved test.

Key features of the study:

• This report provides in-depth analysis of the global PD-1 and PD-L1 inhibitor market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global PD-1 and PD-L1 inhibitor market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Pfizer Inc., Novartis, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, and Regeneron Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global PD-1 and PD-L1 inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PD-1 and PD-L1 inhibitor market.

• Global PD-1 and PD-L1 Inhibitor Market By Type of Inhibitor:
• PD-1 Inhibitors
• PD-L1 Inhibitors
• Global PD-1 and PD-L1 Inhibitor Market By Application:
• Hodgkin Lymphoma
• Kidney Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Others
• Global PD-1 and PD-L1 Inhibitor Market By End Users:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global PD-1 and PD-L1 Inhibitor Market By Geography:
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America
• Company Profiles:
• Pfizer Inc.
• Novartis AG
• AstraZeneca PLC
• Gilead Sciences Inc.
• Amgen Inc.
• Sanofi AG
• Hoffmann-La Roche AG
• Merck & Co.
• Bristol-Myers Squibb Company
• Regeneron Pharmaceuticals Inc.